Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

43.54
-0.4600-1.05%
Post-market: 43.610.0700+0.16%19:56 EDT
Volume:2.31M
Turnover:100.67M
Market Cap:7.24B
PE:-12.51
High:44.17
Open:44.17
Low:43.24
Close:44.00
52wk High:86.74
52wk Low:43.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.63
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:16.45
PE(LYR):-18.28

Loading ...

Ionis Pharmaceuticals Inc : Piper Sandler Raises Target Price to $110 from $100

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 25

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jun 25

Ionis Licenses Alexander Disease Drug Zilganersen to Recordati Outside US for $30 Million Upfront

Reuters
·
Jun 25

Ionis Pharmaceuticals - Plans Independent U.S. Launch of Zilganersen; FDA Pdufa Date Set for September 22

THOMSON REUTERS
·
Jun 25

Ionis Announces License Agreement with Recordati for Zilganersen in Alexander Disease (axd) in All Countries Outside the U.S.

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - to Retain U.S. Commercial Rights and Lead Global Development of Zilganersen

THOMSON REUTERS
·
Jun 25

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza Available in 50 Mg or 80 Mg Dose, Self-administered Monthly

THOMSON REUTERS
·
Jun 25

Tryngolza® (olezarsen) Approved by the FDA as the First and Only Treatment to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia (shtg)

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza to be Available in U.S. for Shtg in July

THOMSON REUTERS
·
Jun 25

FDA: Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Jun 25

Ionis' Tryngolza Receives FDA Approval to Treat Acute Pancreatitis in Severe Hypertriglyceridemia Patients

MT Newswires Live
·
Jun 25

FDA announces approval of Ionis’ Tryngolza for hypertriglyceridemia

TIPRANKS
·
Jun 24

How Olezarsen’s Longer-Term Hepatic Data and High Retention Could Shape Ionis Pharmaceuticals (IONS) Investors

Simply Wall St.
·
Jun 20

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Ionis director Spencer R. Berthelsen sells 8,000 shares worth $587,920

Reuters
·
Jun 17